Application of programmed cell death protein 1/programmed death-ligand 1 blockade in advanced gastric cancer treatment / 上海交通大学学报(医学版)
Journal of Shanghai Jiaotong University(Medical Science)
; (12): 1259-1264, 2018.
Article
in Zh
| WPRIM
| ID: wpr-843600
Responsible library:
WPRO
ABSTRACT
In the tumor microenvironment, the interaction of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) can promote the immune escape of tumor cells. The application of PD-1/PD-L1 blockade can restore host immune function to efficiently identify and kill tumor cells. In recent years, PD-1/PD-L1 blockade has shown remarkable clinical effects in a variety of tumors and U.S. Food and Drug Administration has approved nivolumab and pembrolizumab for the treatment of unresectable/metastatic melanoma, non-small cell lung cancer and etc. Hence, a growing number of clinical trials on PD-1/PD-L1 blockade for advanced gastric cancer have been carried out, and the overall survival and objective response rate of most trials are promising. This paper reviewed PD-1/PD-L1 signaling pathway, the relationship between the expression of PD-L1 and the classification and prognosis of gastric cancer, and the clinical results of PD-1/PD-L1 blockade in advanced gastric cancer.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Journal of Shanghai Jiaotong University(Medical Science)
Year:
2018
Type:
Article